Submit a comment

Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene.
L Grunebaum, J P Cazenave, G Camerino, C Kloepfer, J L Mandel, P Tolstoshev, M Jaye, H De la Salle, J P Lecocq
L Grunebaum, J P Cazenave, G Camerino, C Kloepfer, J L Mandel, P Tolstoshev, M Jaye, H De la Salle, J P Lecocq
View: Text | PDF
Research Article

Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene.

Abstract

The cloned complementary DNA for coagulation Factor IX (FIX) detects a frequent restriction fragment length polymorphism (RFLP) in human genomic DNAs digested with the restriction endonuclease Taq I. This genetic marker was used, in parallel with coagulation and immunological assays, to follow the segregation of an abnormal FIX gene in a large Hemophilia B family. Among the six potential female carriers, functional assays showed that four had a high probability, and two a low probability of being carriers. Analysis at the DNA level with the cDNA probe was informative in five of the six cases, and in all these five the diagnosis of carrier state was definitively confirmed. This demonstrates the feasibility of using linkage analysis at the DNA level for the genetic screening of Hemophilia B. This method has the advantages over conventional assays of giving a diagnosis of certainty, and of being applicable to early prenatal diagnosis using biopsies of trophoblast villi. At present, the single known polymorphism associated with the FIX gene restricts the application of linkage analysis to informative cases (40%), but findings of additional RFLPs in this region should improve this figure.

Authors

L Grunebaum, J P Cazenave, G Camerino, C Kloepfer, J L Mandel, P Tolstoshev, M Jaye, H De la Salle, J P Lecocq

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required